当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

Citeline:2025年JPM医疗健康大会会后报告(中译版)(86页).pdf

上传人: Y**** 编号:621469 2025-04-02 86页 1.90MB

下载:

1、W ATS T E BIG DAL?JPM2025 POST-EVENT REPORT Go beyond the headlines with our expert analysis of the biggest news from the J.P.Morgan Healthcare Conference.Sponsored by 2 January 2025 Copyright 2025 Pharma Intelligence UK Limited(Citeline),a Norstella company(Unauthorized photocopying prohibited)Summ

2、ary The 43rd annual J.P.Morgan Healthcare Conference(JPM)was held in San Francisco,CA over Jan.1316,2025.This report contains presentation highlights from a selection of companies from the conference in a single destination.A complete list of events and catalysts that were announced or updated is in

3、cluded as a supplement to the report.About the Author Biomedtracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database.Clients from the pharmaceutica

4、l,biotech,and investment industries rely on Biomedtracker for its insight on the likelihood of approval,commercial potential,and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.Over the last several years,Biomedtracker has bec

5、ome the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide.For more information on getting direct access to Biomedtracker,please email .Disclaimer Copyright 2025 Pharma Intelligence UK Limited(Citeline),a Norste

6、lla company This report is published by Citeline(the Publisher).This report contains information from reputable sources and although reasonable efforts have been made to publish accurate information,you assume sole responsibility for the selection,suitability and use of this report and acknowledge t

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了2025年J.P.摩根医疗保健会议上的公司报告,包括AbbVie、AstraZeneca、Intuitive Surgical、Merck & Co、Novartis、Alnylam Pharmaceuticals、BioMarin Pharmaceuticals、Bristol Myers Squibb、Cooper Companies、Genmab等大型制药公司的最新动态和战略规划。 AbbVie的CEO Rob Michael强调了公司当前的强劲地位,预计未来8年将实现稳定增长。AstraZeneca的CFO Aradhana Sarin介绍了公司五大治疗领域的发展,包括肿瘤学、心血管、肾脏和代谢、呼吸和免疫学、疫苗和免疫疗法以及罕见病。Intuitive Surgical的CEO Gary Guthart报告了公司2024年的业绩和2025年的战略重点。Merck & Co的CEO Robert Davis和Dr. Dean Li总结了公司在过去三年半里执行战略优先事项的进展。Novartis的CEO Dr. Vas Narasimhan强调了公司对创新药物的承诺,并概述了其核心治疗领域的资产和技术平台。Alnylam Pharmaceuticals的CEO Yvonne Greenstreet介绍了公司的五个已批准产品和超过25个管道发展项目。BioMarin Pharmaceuticals的CEO Jean-Jacques Bienaime讨论了公司的业务基础,包括传统的酶基疗法和蛋白质类似物。Bristol Myers Squibb的CEO Chris Boerner强调了公司为成为本十年最快增长的公司之一所做的努力。Cooper Companies的CEO Alastair Kerr概述了公司的两大业务部门CooperVision和CooperSurgical的成功和前景。Genmab的CEO Jan van den Winkel强调了公司成为“全面集成的生物技术创新力量”的目标。
哪些药物是Genmab公司拥有50%以上股份的? Genmab公司的KYSO抗体药物如何改变癌症患者的生活? Genmab公司计划如何通过创新和差异化的抗体疗法改善患者的生活?
客服
商务合作
小程序
服务号
折叠